Eisai Inc. $4523.T
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-33
RECRUITING2
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO71%
Delay Index: of 7 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +33.8 months). See all sponsors →
Open Eisai Inc. on the live radar map → 📅 $4523.T readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| CLEAR NCT02811861 |
P3 | Active, not recruiting | Renal Cell Carcinoma | 1069 | 2020-08-28 (-2 mo) |
| E2814 NCT06602258 |
P2 | Active, not recruiting | Alzheimer's Disease | 105 | 2026-12-03 (+6 mo) |
| Clarity AD NCT03887455 |
P3 | Active, not recruiting | Early Alzheimer's Disease | 1906 | 2026-12-31 (+34 mo) |
| E2086 NCT07493265 |
P2 | Recruiting | Narcolepsy | 64 | 2027-02-14 |
| E7386 NCT04008797 |
P1/2 | Active, not recruiting | Endometrial Neoplasms; Neoplasms | 301 | 2027-03-31 (+72 mo) |
| Perampanel Oral Suspension NCT04015141 |
P2 | Active, not recruiting | Pediatric Epileptic Syndrome; Partial-onset Seizures | 100 | 2027-04-06 (+66 mo) |
| Lecanemab NCT04468659 |
P3 | Active, not recruiting | Preclinical Alzheimer's Disease; Early Preclinical Alzheimer's Disease | 1400 | 2028-12-21 (+14 mo) |
| Farletuzumab ecteribulin NCT04300556 |
P1/2 | Recruiting | Solid Tumor | 182 | 2030-08-08 (+93 mo) |